OMNIX MEDICAL: UN PAPILLON CONTRE ACINETOBACTER BAUMANNII

Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6 (A Poster)

Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6, a Novel Antimicrobial Peptide for Acinetobacter baumannii (AB), Conducted in Healthy Volunteers Access

Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6

Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for

Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6

JERUSALEM, Israel, November 20, 2023 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the U.S.

OMNIX MEDICAL: UN PAPILLON CONTRE ACINETOBACTER BAUMANNII

More To Explore

Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6 (A Poster)

Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6

Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6

Contact Us

Reach US